



HTRS 2021 SCIENTIFIC SYMPOSIUM  
March 11-13, 2021 – Loews Coronado Bay, San Diego, CA  
**HTRS ABSTRACT ACCEPTANCE POLICY & SUBMISSION INSTRUCTIONS**

---

***Registration and Abstract Submission are now open, as of Tuesday, September 1, 2020.***

***The Call for Abstracts will close on Thursday, October 15, 2020.***

***Please stay tuned: HTRS is continually monitoring public health concerns and restrictions due to COVID-19 and may make adjustments related to hosting the meeting as a hybrid (in-person and virtual) or virtual meeting platform. Thanks for your patience.***

***ABSTRACT SUBMISSION PORTAL: [CLICK HERE](#)***

***SYMPOSIUM SITE LINK: [CLICK HERE](#)***

---

## **1. General Information**

The HTRS 2021 Scientific Symposium (“HTRS 2021” or “the meeting”) is a forum for presenting original clinical, translational, or basic science research findings in benign hematology.

HTRS accepts abstracts on clinical care and research in disorders of hemostasis and/or thrombosis from:

- Physician Scientists working in academic medicine or industry
- Research Scientists
- Trainees (students/residents/fellows)
- Allied Health Professionals (Nursing/Physician Assistants/Pharmacists/PharmDs)
- Other Research Professionals (not categorized above)

Authors of accepted abstracts may present their abstracts as oral presentations or posters during the meeting. Accepted abstracts will be published in a summer 2021 issue of an HTRS-affiliated professional journal to be announced prior to the meeting. Abstracts submitted in the “Informational Only” category (described further

in Section 8) may be accepted as posters but are not eligible for Travel Awards, oral presentations, or publication.

## 2. HTRS 2021 Abstract Submission Deadline

Abstracts for HTRS 2021 are due on or before **Thursday, October 15, 2020 at 11:59 p.m. ET.**

Abstracts cannot be revised or resubmitted after this deadline. Only online submissions will be accepted at <https://www.abstractscorecard.com/cfp/submit/login.asp?EventKey=DIDXRFCG>.

Accepted abstracts will be published exactly as submitted. (Authors may make corrections or updates to their posters after the abstract submission deadline, but not to the abstracts themselves.) Late abstracts will not be accepted. The submission link will be deactivated after **Thursday, October 15, 2020 at 11:59 p.m. ET.**

## 3. HTRS Abstract Acceptance Policy

Abstracts will be accepted by HTRS if submitting authors meet the following criteria:

- a. Abstracts should describe original work.
  - i. Abstracts must contain new data. Abstracts previously presented at a national or international meeting may not be submitted without modification; data must be updated or expanded, resulting in a new abstract.
  - ii. Any abstracts previously presented in a substantive way must be accompanied by a justification statement (or appeal) of three sentences or less to explain why the abstract should be accepted for presentation at HTRS. The HTRS Review Committee will consider such appeals.
  - iii. Data featured in the abstract may not be published before presentation at the meeting. HTRS reserves the right to decline previously published abstracts.
  - iv. The abstract/data submitted to HTRS should not be submitted to other meetings before the HTRS 2021 Symposium takes place. After the 2021 meeting, the abstract may be submitted as an encore item to other meetings if their policy allows.
- b. The Presenter must be an author of the abstract; if the abstract is a "presentation on behalf of X study group," the presenter must be a member of said study group.
- c. The title and body of the abstract must not contain:
  - Personal patient information
  - Studies reporting unidentified chemical compounds, drugs, or materials
  - Non-generic drug names (generic drug names may be used in a footnote at the bottom of the abstract)

The title of the abstract must not contain commercial company names (commercial company names may be used in the body of the abstract or as a footnote of the abstract if the name thereby better identifies a product or device)
- d. The submitting author will be asked to certify the following statements prior to uploading an abstract to the online submission site:

- The reported research complies with all applicable animal welfare and human subject regulations.
  - HTRS is being given unrestricted, irrevocable permission to publish and/or post the abstract in print material, in an online journal partnering with HTRS, on the meeting website, and on the HTRS website. (The first author retains the abstract’s copyright; anyone wishing to use the abstract post-meeting will be instructed to contact the first author for permission.)
- e. The presenting author must be willing to answer all questions from the audience in good faith if the abstract is selected for oral presentation.

#### 4. Review and Selection Process

All abstracts undergo blind peer review. The HTRS Abstract Review Committee evaluates submissions on scientific merit, applicability to current issues in hemostasis and thrombosis, novelty, and writing quality.

#### 5. Oral Presentations for Travel Award Recipients

Up to twenty-four (24) 2021 Travel Awards will be offered to the first authors of outstanding abstracts submitted by trainees and/or early-career investigators. HTRS will select the abstracts from Travel Award recipients, as designated below, to be presented during one of four oral abstract sessions during the meeting.

- Presenting authors must be the first authors of selected abstracts.
- Presenting authors will be given 10 minutes to discuss their abstract, immediately followed by a three-minute question-and-answer period.
- Details about oral abstract presentation and instructions for preparing slides will be sent to presenting author in early February 2021 along with poster presentation instructions.
- Abstracts selected for oral presentation may also be presented as a poster during the meeting.

#### 6. HTRS Travel Awards

***Please stay tuned: HTRS remains fully committed to distinguishing top abstracts with awards in 2021; however, adjustments may be made to the awards themselves, contingent on travel restrictions due to ongoing public health concerns.***

---

HTRS Travel Awards reimburse awardees for the cost of airfare, ground transportation, lodging for two nights, and meals on travel days, to attend the meeting, up to a not-to-exceed total of \$1,500.00 USD. Travel Award recipients also receive waived meeting registration; only one award per person is allowed.

HTRS will offer awards to investigators who meet the following criteria:

- At least 18 awards will be given to first authors of the highest-scoring abstracts submitted by trainees or early career investigators working at non-commercial institutions (please refer to the definition of “trainees” and “early career investigators” below)

- Up to two awards will be given to first authors of an abstract submitted by allied health professionals at any stage in their careers, working at a non-commercial institution
- Up to two awards will be given to first authors of an abstract submitted by individuals who qualify as an underrepresented minority (<https://diversity.nih.gov/about-us/population-underrepresented>) at any stage in their careers, working at a non-commercial institution
- Up to one award will be given to the first author of an abstract submitted by an undergraduate student at any stage in his/her career, working at a non-commercial institution
- Up to one award will be given to the first author of an abstract submitted by an investigator at any stage of his/her career from North or Central America, working at a non-commercial institution

HTRS defines “trainees” as:

- **Medical Fellows:** MDs/MBBSs or DOs enrolled in accredited fellowship training programs. Fellows must be:
  - In training for a career in hemostasis and/or thrombosis
  - OR
  - In training for a career that will have a substantial component of, or overlap with, the disciplines of hemostasis and/or thrombosis (such as ob/gyn or cardiology)
- **Postdoctoral Fellows:** PhDs pursuing academic research in benign hematology
- **Medical Residents: MDs/MBBSs or DOs** pursuing a fellowship in benign hematology
- **Medical students** interested in benign hematology
- **Graduate students** interested in pursuing research in benign hematology
- **Undergraduate students** interested in pursuing research in benign hematology

HTRS defines “early-career investigators” as:

- **Junior attending and junior faculty** (MDs/MBBSs, DOs, PhDs) working in non-commercial institutions who are:
  - Within five years of completing training for a career in hemostasis and/or thrombosis at the time of the abstract submission deadline
  - OR

- Within five years of completing training for a career that will have a substantial component of, or overlap with, the disciplines of hemostasis and/or thrombosis (such as ob/gyn or cardiology) at the time of the abstract submission deadline

HTRS defines “allied health professionals” as any of the following who are interested in pursuing research in benign hematology:

- Nurses/Nurse Practitioners
- Physician Assistants
- Pharmacists
- Physical Therapists
- Medical Technologists or Other Laboratory Professionals
- Genetic Counselors
- Social Workers

## 7. **“Abstracts of Distinction”**

The top-scoring abstracts submitted by investigators who are not eligible for the Trainee/Early-Career Investigator category and who work for non-commercial institutions will be recognized as “Abstracts of Distinction.” Authors of abstracts receiving this designation may be invited to give an oral presentation and present a poster during the meeting. Only authors of selected abstracts may give oral presentations and present posters at the meeting.

- It is preferred, but not mandated, that the presenting author be the first author of the abstract submitted in this category
- Presenters will be given 10 minutes to discuss their abstracts, immediately followed by a three-minute question-and-answer period
- Details about oral abstract presentation and instructions for preparing slides will be sent to the presenting author in early February 2021 along with poster presentation instructions

## 8. **“Informational Only” Abstracts**

Abstracts may be submitted for informational purposes only to be displayed as posters at the conference. “Informational Only” abstracts are not eligible for Travel Awards, designation as “Abstracts of Distinction,” oral presentations, or publication.

- Informational Only abstracts generally do not contain original data
- Examples of Informational Only abstracts include: news about a new or existing registry, news about a new or existing study, news about a new society or meeting being organized, information about a novel practice or service (i.e. use of telemedicine for consults), or a single case report/very small case series (of note, for case reports and series, exceptions may be made if the abstract presents particularly compelling/new information on a rare disorder)

## 9. Preparing Your Abstract

Please follow these instructions to prepare your abstract or abstracts for submission. Proofread carefully to avoid errors before submission. HTRS is not responsible for editing or re-formatting accepted abstracts prior to publication.

- a. Required language: English
- b. Download and agreeance to the 'HTRS 2021 Abstract Acceptance Policy & Submission Instructions'
- c. Authors: Last name, first name, degrees, affiliations, city, state, country, and contact information
- d. Maximum of 3,000 characters including spaces (not including the title, authors, or affiliations)
- e. Abstract text should preferably be in a "structured abstract" form with sections clearly marked Background, Objectives, Methods, Results, and Conclusions
- f. Maximum of 2 relevant tables or figures. Please submit figures in .jpg format at a minimum of 600 dpi. Figures that do not meet these minimum formatting requirements will be excluded from publication
- g. References must be included as parenthetical in-text citations: first author, et al, journal and year (e.g. Cruz D, et al. Blood 2012)
- h. Abstracts containing non-generic drug names in the title or body of the abstract, personal patient information, or reporting studies with unidentified chemical compounds, drugs, or materials will not be accepted. (Non-generic drug names may be used in a footnote at the bottom of the abstract but not in the title or body of the abstract.) Abstracts containing drug manufacturers' company names in the title of the abstract will not be accepted, but a drug manufacturer's company name can appear in the body or footnote of the abstract if it thereby better identifies a product or device
- i. Full contact information for the corresponding author (please ensure that your email address is accurate, as all correspondence will be sent via email)
- j. Additional required questions:
  1. Is the presenting author an early stage investigator ("ESI")?
    - If yes, are they interested in applying for an abstract award?
    - If yes, name of abstract award applicant/ESI applicant:
    - Does this applicant meet the award requirements? Please indicate month/year that training/fellowship was completed in the box below:
  2. Was this abstract containing the exact same data previously submitted to / presented at another meeting occurring before the HTRS 2021 Symposium? If **yes**, you may NOT submit the abstract unless it contains new, updated or expanded data.
    - If yes, what was the name and date of the meeting?
    - If yes, was this meeting held in-person, both in-person and virtual, or completely virtual?
- k. Successfully completed tasks will have a green check mark
- l. After all tasks are completed, select the 'Preview & Submit' button at the bottom of the task list
- m. Review your submission and then select the 'Submit' button in the upper right corner
- n. A confirmation email will be sent to the submitter's email address

## **10. Poster Presentation Sessions and General Viewing of Posters**

The Poster Presentation Session will be held in the HTRS 2021 Exhibit Tent; poster presenters must be on hand at designated times to answer questions about their posters.

Only authors of accepted abstracts may present posters or give oral presentations.

## **11. Responsibilities of Abstract/Poster Presenters**

### **Presenting Authors Who are Travel Award Recipients**

- HTRS will reserve lodging within the HTRS 2021 Room Block for two nights at the meeting hotel
- In order to receive complimentary registration, Travel Award recipients must register in advance for the meeting using a special registration code that will be provided in their notification of abstract acceptance
- Travel Award recipients must make their own airfare and ground travel arrangements.

### **Presenting Authors Not Selected for Travel Awards**

- Must register to attend the meeting
- Are responsible for all expenses related to participating in the meeting, including registration fees, transportation, lodging, and any meals outside of those provided by HTRS as part of the general conference

## **12. Notification**

Notification of abstract acceptance for poster presentation, Travel Awards, and/or Abstracts of Distinction will be made the week of December 14, 2020.

## **13. For More Information**

Questions regarding HTRS 2021 abstract submission should be directed to Danielle Barsuglia at [contact@htrs2021.org](mailto:contact@htrs2021.org) or Jennifer Ziegler at [jziegler@versiti.org](mailto:jziegler@versiti.org).